A Phase 3 interventional study of Abenacianine and Near Infrared (NIR) Imaging in Lung Cancer and Lung Metastases, sponsored by Vergent Bioscience, Inc.. Recruiting at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Vergent Bioscience, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,462 studies in Lung Neoplasms with a site in United States — 423 open to participants now, 644 under way, 52 of them phase 3. Lung Neoplasms · United States.
Among the 2,462 studies in Lung Neoplasms with a site in United States, this one is the 474th largest by planned enrollment of the 1,908 interventional ones that give a count, is one of 112 that started in 2026, is one of 158 in phase 3, reaches primary completion later than 146 of the 638 other live ones, and was the 2,397th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →423 of the 2,462 studies in Lung Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 50–77 · Healthy volunteers
Fred Hutchinson Cancer Center · Sites in United States
Ages 50–80 · Healthy volunteers
Roswell Park Cancer Institute · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,462 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 660 · Phase 2 866 · Phase 3 179 · Phase 4 21
First in 1990; this study’s year is marked. 112 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 132 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 48 across the 1,908 interventional studies, 123 across the 442 observational. Of the 1,674 that completed or were terminated, 583 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
620 of 2,462 have an industry lead sponsor. The 10 most frequent:
Vergent Bioscience, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Vergent Bioscience, Inc. has 3 studies filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
243 of the studies in Lung Neoplasms with a site in United States that are under way reach primary completion within a year, 13 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07499674Phase 3Vergent Bioscience, Inc.Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung | 2026-12 |
| NCT06151574Phase 3Boehringer IngelheimBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | 2026-12-10 |
| NCT03637816Phase 3M.D. Anderson Cancer CenterAnamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer | 2026-12-31 |
| NCT04093167Phase 3Canadian Cancer Trials GroupStudy of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer | 2026-12-31 |
| NCT03391869Phase 3M.D. Anderson Cancer CenterNivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | 2027-03-31 |
Add all 243 to your calendar (.ics) → With an account.
Among the 2,462 studies in Lung Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging in participants undergoing surgery for cancer in the lung. Approximately 132 partiipants will be enrolled to ensure a minimum of 115 evaluable participants receiving abenacianine and undergoing NIR imaging and a control group of 12 participants who will receive abenacianine but no NIR imaging.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Be able to meet the following conditions:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this arm will receive abenacianine 0.31mg/kg 12-96 hours before undergoing surgery using SOC only.
Drug: Abenacianine
Participants randomized to this arm will receive abenacianine 0.31mg/kg 12-96 hours before undergoing surgery using SOC plus NIR imaging.
Drug: Abenacianine · Other: Near Infrared (NIR) Imaging
Intravenous drug to be given by syringe pump.
NIR imaging is a non-visible, optical technique capturing light just beyond human vision, allowing high-contrast imaging.
Identify the proportion of participants with at least one Clinically Significant Event (CSE) as defined by:
A. Intraoperative localization of one or more preoperatively identified lung lesions using abenacianine with NIR imaging when standard surgical techniques using white light with or without palpation fail to identify the lesion(s). B. Identification of one or more synchronous or occult lung lesions using abenacianine with NIR imaging when standard surgical techniques using white light with or without palpation and preoperative imaging fail to identify the lesion(s).
Time frame: Day of Surgery
Key Secondary Endpoints
To evaluate the Population False Positive Rate for lesions (PFPR-L). A false-positive lesion is defined as tissue that fluoresces and is determined by histopathology to be normal (non-pathological).
Time frame: Upon receipt of histopathology report (~2-3 weeks post surgery)
Key Secondary
To evaluate the Population False Positive Rate for lymph nodes (PFPR-LN). A false-positive lymph node is defined as a resected lymph node that fluoresces and is determined by histopathology to be non-cancerous.
Time frame: Upon receipt of histopathology report. (~2-3 weeks post surgery)
Key Secondary
To evaluate the proportion of participants who have at least one lymph node resected due to fluorescence that would not have been removed under the protocol defined standard of care (SOC) and is confirmed by histopathologic examination to be cancerous.
Time frame: Upon receipt of histopathology report. (~2-3 weeks post surgery)
Other Secondary Endpoints
To evaluate the sensitivity and specificity of abenacianine.
Time frame: Day of surgery
Pharmacokinetic Endpoint
Determine the maximum plasma concentration (Cmax) of abenacianine.
Time frame: Pre-dose through 24 hours post-dose
Pharmacokinetic Endpoint
Determine the time to reach the maximum plasma concentration (Tmax) of abenacianine.
Time frame: Pre-dose through 24 hours post-dase
Plan to share: No — The joint publication will be coordinated by Vergent. There is no need for individual sites to review specific IPD from other sites.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.
Of 62 industry-sponsored phase 3 interventional studies under Lung Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 44. This study's planned 9 months is below that.
Counting every sponsor, half of 127 studies reached it within 43 months; a quarter within 30 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vergent Bioscience, Inc.